A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Running, not enrolling · Phase 3

Conditions studied: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

In brief

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

Key facts

Study ID
NCT04002297
Run by
BeOne Medicines
People needed
510
Starts
2019-08-20
Expected to finish
2031-09-30
Last updated by the study team
2026-05-18

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.